SPI Infoamtion

Table of Contents

Executive Summary

Overview of India
The Indian healthcare system
The pharmaceutical industry in India
Key players in the Indian pharmaceutical market

Indian pharmaceutical market SWOT analysis

Chapter 1 Scope and methodology

Scope
Methodology

Scope of IMS data

Chapter 2 Overview of India

Summary
Introduction

Overview of Indian history

The government
A burgeoning economy

Key economic parameters
An imprint of the global slowdown

Population profile and demographic trends
Disease burden

Vector-borne diseases

Chapter 3 The Indian healthcare system

Summary
Introduction
Healthcare system

The rural healthcare system
The urban healthcare system
Specialist and emergency medical care

The regulatory set-up
Intellectual property rights

Effect of IPR regime on innovation

Financing healthcare

Inefficiencies fueled by underutilization of funds

Pricing and reimbursement
Private health insurance

Private healthcare

A range of private healthcare services
Public-private partnerships

Alternative medicine: AYUSH

Ayurveda
Yoga
Naturopathy
Unani
Siddha
Homoeopathy

Chapter 4 The pharmaceutical market in India

Summary
Introduction
Key market trends, events and issues
Therapy area analysis
Therapy area sales forecast
Leading brands
Leading brands sales forecast
Over-the-counter medication
The Indian generics advantage

Chapter 5 Key players in the Indian pharmaceutical market

Summary
Introduction
Leading players of the Indian pharmaceutical market
Detailed analysis of the Indian pharmaceutical market players

Cipla

Overview
Sales focus by leading drug classes
Sales focus by leading brands
New product launches
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

Ranbaxy

Overview
Sales focus by leading drug classes
Sales focus by leading brands
R&D pipeline analysis
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

GlaxoSmithKline (India)

Overview
Sales focus by leading drug classes
Sales focus by leading brands
R&D pipeline analysis
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

Piramal Healthcare

Overview
Sales focus by leading drug classes
Sales focus by leading brands
R&D pipeline analysis
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

Zydus Cadila

Overview
Sales focus by leading drug classes
Sales focus by leading brands
R&D pipeline analysis
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

A snapshot of other key market players

Sun Pharma
Lupin
Alkem
Sanofi-Aventis
Mankind Pharma

Leading players in the Indian pharmaceutical market: sales forecast

Chapter 6 Appendix

IMS data
Anatomical Therapeutic Classification (ATC)

A: Alimentary tract and metabolism
B: Blood and blood-forming organs
C: Cardiovascular system
D: Dermatologicals
G: Genito-urinary system and sex hormones
H: Systemic hormonal preparations
J: General anti-infectives systemic
L: Antineoplastic and immunomodulating agents
M: Musculo-skeletal system
N: Nervous system
R: Respiratory system
S: Sensory organs
T: Diagnostic agents
V: Various

Glossary
Index

List of Figures
Figure 1.1: Indian pharmaceutical market SWOT analysis
Figure 2.2: Real GDP growth rate at factor cost across different quarters of the fiscal years 2008 and 2009 (%)
Figure 2.3: Comparative position ($bn) of India among the top service exporters globally, 2007
Figure 2.4: Deaths by cause for non-communicable diseases in India, 2005
Figure 3.5: Total expenditure on health per capita ($) in seven emerging pharmaceutical markets, 2006
Figure 3.6: Rural healthcare network in India
Figure 3.7: Public spending on healthcare (% GDP) in India, 1950-2006
Figure 4.8: Comparative position of India among the different global markets, 2008
Figure 4.9: Top 10 drug classes of the alimentary tract and metabolism therapy area ($m), 2008
Figure 4.10: Top 10 drug classes of the anti-infective therapy area ($m), 2008
Figure 4.11: Top 10 drug classes of the cardiovascular system therapy area, ($m) 2008
Figure 4.12: Top 10 drug classes of the respiratory system therapy area ($m), 2008
Figure 4.13: Top 10 drug classes of the nervous system therapy area ($m), 2008
Figure 4.14: Therapy area sales growth trend, 2004-08
Figure 5.15: Market share of leading players in the Indian pharmaceutical market (%), 2008
Figure 5.16: Cipla's Indian market sales by therapy area ($m), 2008
Figure 5.17: Cipla's SWOT analysis
Figure 5.18: Ranbaxy's Indian market sales by therapy area ($m), 2008
Figure 5.19: Ranbaxy's SWOT analysis
Figure 5.20: GSK's Indian market sales by therapy area ($m), 2008
Figure 5.21: GSK (India) SWOT analysis
Figure 5.22: Piramal Healthcare's Indian market sales by therapy area ($m), 2008
Figure 5.23: Piramal Healthcare's SWOT analysis
Figure 5.24: Zydus Cadila's Indian market sales by therapy area ($m), 2008
Figure 5.25: Zydus Cadila's SWOT analysis

List of Tables
Table 2.1: Political snapshot of India
Table 2.2: Economic snapshot of India
Table 2.3: Demographic snapshot of India
Table 2.4: Ten leading causes of death (%) in India, 2002
Table 2.5: Forecast epidemiology of major diseases in India, 2008-14
Table 2.6: Vector-borne diseases in India
Table 4.7: Indian pharmaceutical market by therapy area sales, 2008
Table 4.8: Indian pharmaceutical market therapy area sales forecast ($m),
Table 4.9: Indian pharmaceutical market by leading brands, 2008
Table 4.10: Top 10 brands of the Indian pharmaceutical market, sales forecast 2008-14
Table 5.11: Leading players of the Indian pharmaceutical market by sales, 2008
Table 5.12: Cipla's leading brands in the Indian market (($m), 2008
Table 5.13: Leading recently launched products of Cipla in the Indian market
Table 5.14: Leading brands of Daiichi-Ranbaxy in the Indian market ($m), 2008
Table 5.15: Leading pipeline compounds of Ranbaxy in the Indian market
Table 5.16: Leading brands of GSK in the Indian market, 2008
Table 5.17: Key patented products of GSK launched in India
Table 5.18: Leading brands of Piramal Healthcare in the Indian market, 2008
Table 5.19: Piramal Healthcare's key acquisitions
Table 5.20: Piramal Healthcare's key alliances and licensing agreements
Table 5.21: Leading brands of Zydus Cadila in the Indian market, 2008
Table 5.22: Key pipeline drugs for Zydus Cadila
Table 5.23: Leading players in the Indian pharmaceutical market, sales forecast 2008-14